News
We take pride in our achievements and want to share our successes with you.
Updates on our latest news on IBsolvMIR will be added as soon as it’s available.

NEWS

4 March 2019
TFS International AB (TFS) appointed CRO representative for TIKOMED’s phase 2 study in clinical islet transplantation
Viken – 4th March 2019 – TIKOMED, a Swedish privately held biopharmaceutical company today announced…
Read More
8 February 2019
TIKOMED successfully closed fundraising of 8 Million Euros
Viken – 8th February 2019 – TIKOMED, a Swedish privately-held biopharmaceutical company today announced its…
Read More
6 February 2019
Shadow Lake Group appointed Strategic Advisor and Business Development representative for the licensing process of IBsolvMIR® in Canada
Viken – 6th February 2019 – TIKOMED, a Swedish privately held biopharmaceutical company today announced…
Read More
30 November 2018
TIKOMED Granted Permission for Phase 2 Clinical Trial in Islet Cell Transplantation by the Swedish Medical Product Agency
VIKEN, Sweden, November 19, 2018 (Newswire) -TIKOMED, a specialty pharmaceutical company developing IBsolvMIR, an infusion…
Read More
24 July 2018
TIKOMED is looking for an experienced Project Leader
We are looking for you who are passionate, skilled and with strong track record and…
Read More
5 June 2018
Anders Kristensson appointed CEO of TikoMed
Viken – 18th June 2018 TikoMed, a privately-held biopharmaceutical company today announced the appointment of…
Read More
22 April 2018
TIKOMED IS INTERVIEWED AT BIOSPRING ABOUT IBSOLVMIR FOR IMPROVED CELL-THERAPIES BY MIKE WARD
TikoMeds promising Phase 2 project for more efficient cell-therapies was presented at BioEurope Spring in…
Read More
22 March 2018
TIKOMED PRESENTS IBSOLVMIR AT BIO EUROPE
IBsolvMIR is TikoMed’s original project addressed at alleviating the ”Instant Blood Mediated Inflammatory Reaction” that…
Read More

SUBSCRIBE